Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study
Recruiting
N/A
Interventional Study
Testicular Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 50
- Sex
- Male
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 192 (estimated)
- Sponsor
- University Medical Center Groningen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cisplatin-combination chemotherapy causes inevitably DNA damage by platinum-DNA adduct formation of both tumor cells but also healthy cells. It therefore stands to reason that testicular cancer treatment causes an increased burden of senescent cells, which causes upregulation of the SASP resulting in a pro-inflammatory phenotype. The investigators hypothesize that this may be an important mechanis…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
In order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria:
* Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher)
* Received first-line cisplatin-based chemotherapy
* Was younger …
Contacts